CD8A and melanoma: Pathological response predictive for clinical outcome to immunotherapy has been reported early after initiation of anti-PD-1 in melanoma [34,46] and the accumulation of CD8+ T-cells expressing inhibitory receptors (exhausted T-cells, Tex) was detected in the peripheral blood within 3 weeks after immunotherapy initiation [46,47,48].